On Tuesday (17), HAPV3 shares climbed more than 10% without any new disclosures from Hapvida. The market bought into the premise that the company will sell hospitals and use the proceeds to pay down debt. By Thursday (19), Hapvida itself warned that no such sale has been decided yet. Therefore, investors currently holding the stock are paying for a possibility, not a fact.
HAPV3 Today: Why Did the Stock Jump 10%?
According to Suno Notícias, the shares spiked as much as 10.11%, trading at R$ 5.99 at 1:08 PM. By the close, the gain was even larger: the stock rose 12.5% to finish at R$ 6.12, marking the top performance on the Ibovespa for the day. SpaceMoney reported that no new official statements from the company justified the leap.
Sources diverge on the catalyst. Suno attributed the move to the market digesting third-quarter earnings. Other outlets linked the rally to a report by Broadcast, part of Estadão, which stated that Advent International and Bain Capital were evaluating the acquisition of parts of Hapvida's operations in the South and Southeast. Because the stock surged so sharply without new company disclosures, the second explanation appears more likely. That is our assessment.
The report prompted an inquiry from Brazil's securities regulator, the CVM. In its response published Thursday (19), Hapvida confirmed it is conducting a comprehensive portfolio review. However, the company stated that as of the date of the filing, there are no concrete decisions or binding agreements regarding the reported transaction. In short, the company did not deny the talks, but neither did it confirm any deal. Before looking at a potential sale, it is worth examining the size of the hole this rally is trying to fill.
Where Did the Selloff Come From That This Rally Is Trying to Erase?
The decline began prior to the earnings release. Data compiled from B3 and Yahoo Finance, published on the day of the rally, showed the stock dropping from R$ 8.83 to R$ 3.98 after the second round of elections, before recovering to R$ 6.12 between October 20 and November 17. This scenario was anticipated by UBS, as we highlighted when the bank flagged downside risks for Hapvida and Dasa following the elections.
The recovery has been uneven. The stock closed November 3 at R$ 3.99 and, according to Suno, subsequently strung together four consecutive sessions of gains. It then pulled back 8.39%, trading at R$ 4.37 on the eve of its earnings release. On Monday (16), it fell 4.23%. This constitutes the "selloff" referenced in Suno's headline. On Wednesday (18), the stock rose 3.27% to R$ 6.32 by 3:45 PM.
By our calculations, the stock lost R$ 4.84 between October 20 and November 3 and recovered R$ 2.13 through Tuesday's close. That represents roughly 44% of the drop. While it has rallied 53% from its bottom, it remains 31% below its pre-election price. Over a 12-month horizon, the damage is more pronounced: R$ 10,000 invested in the stock on November 17, 2025, would be worth R$ 3,400 today, excluding dividends. This explains why news of a potential asset sale triggers such a powerful reaction.
What Assets Would Hapvida Be Selling, and How Much Would It Impact Debt?
According to Exame, the package includes eight hospitals, 21 clinics, and 490,000 beneficiaries in the South and Southeast, valued at up to R$ 1 billion. Bain and Advent reportedly are not the only interested parties; the magazine also cites Mubadala and CVC Capital Partners. On Bain's side, the evaluation is reportedly led by Irlau Machado Filho, former CEO of NotreDame Intermédica. A market source consulted by Exame summarized the plan as follows:
“The strategy is to buy the portfolio and build a new NotreDame, taking Hapvida's prime assets.”market source consulted by Exame, on condition of anonymity
This dynamic represents the primary hurdle to a sale. Valor reported, as cited by Focus Poder, that the Pinheiro family, Hapvida's controlling shareholders, would resist negotiating with Bain and Irlau Machado. Machado shared the company's helm with Jorge Pinheiro following the merger and departed in early 2023.
Even so, the financial impact is significant. At the end of September, net debt stood at R$ 5.3 billion, and leverage registered at 1.67x trailing 12-month EBITDA, implying annual EBITDA of roughly R$ 3.2 billion. A R$ 1 billion sale would cut net debt by nearly 19% and reduce leverage to approximately 1.36x. This estimate is our own and assumes the sold assets generate virtually no EBITDA, which aligns with descriptions of underperforming operations. The 490,000 beneficiaries represent about 5.8% of the health plan portfolio. Consequently, JPMorgan views the potential sale positively, according to Bloomberg Línea, as the company would sacrifice minimal revenue while gaining financial breathing room.
For comparison, the sale of real estate tied to Hospital Octaviano Neves, announced on November 11, generated R$ 60 million. The current package would be roughly 16 times larger. However, asset sales only help if the underlying balance sheet can support the rest of the operation, making a close look at the quarter necessary.
HAPV3 Results: Does the 3Q26 Report Justify the Rally?
Partially. The earnings report came in less grim than feared: according to Seu Dinheiro, adjusted profit surpassed consensus projections compiled by Bloomberg, which pointed to R$ 63 million. This drove the stock up as much as 15% on November 12. However, the table below shows that operations deteriorated across nearly all critical lines:
| Metric | 3Q26 | Comparison |
|---|---|---|
| Net revenue | R$ 8.08 billion | +3.9% YoY |
| Adjusted EBITDA (margin) | R$ 496.6 million (6.1%) | −33.5%; margin was 9.6% |
| Adjusted net income | R$ 107 million | −68.3% YoY |
| Accounting result | net loss of R$ 118.8 million | net loss of R$ 57 million in 3Q25 |
| Cash loss ratio (sinistralidade) | 77.2% | 75.2% in 3Q25 |
| Health beneficiaries | 8.43 million | −235,000 in the quarter |
| Net debt / EBITDA | 1.67x | 1.61x in 2Q26; 1.0x in 3Q25 |
Two details alter this interpretation. First, the customer attrition was almost entirely voluntary. According to BB Investimentos, 226,000 cancellations stemmed from contract reviews, while normalized churn was approximately 9,000 lives. The company cut unprofitable contracts. Second, debt decreased by about R$ 100 million during the quarter, aided by the discounted repurchase of bonds. Even so, leverage increased because EBITDA fell faster than debt. An asset sale would help correct this mismatch. Aside from that, meaningful operational improvement is unlikely to materialize before 2027. BTG Pactual maintained a neutral rating with high risk, according to Seu Dinheiro.
Is HAPV3 a Buy Now? And Does It Pay Monthly Dividends?
Monthly dividends, no. The stock does not pay regular dividends. The last distribution recorded on the B3 was interest on equity (JCP) of R$ 0.0054 per share, with an ex-date of December 28, 2021. Given the accounting loss and debt prioritization, there is no realistic expectation of distributions in the near term.
Regarding valuation, our November 16 valuation model estimates a fair value range between R$ 7.84 and R$ 12.70. Even following the rally, the share price sits below the floor of that range, which keeps our site's verdict at a buy. However, the conviction level for this calculation is moderate, and our fundamental score stands at 4.5 out of 10. The stock is discounted because the risks are real. Citi reached a similar conclusion: it maintained a price target near R$ 10 while cutting its profit projections for 2026 and 2027. Asset manager Squadra, one of the major shareholders, acknowledged that the merger thesis has misfired.
Two additional factors remain on the radar. Safra calculated that the elimination of Brazil's six-day workweek schedule could cost up to 4.6% of EBITDA, ranking Hapvida as the most exposed company in the sector. On the positive side, MAK Capital acquired a 5.05% stake purchased near the lows. Investors weighing a potential purchase must balance both sides:
- The potential sale of a package worth up to R$ 1 billion would eliminate nearly a fifth of net debt and remove unprofitable operations from the portfolio.
- Earnings beat consensus, debt declined during the quarter, and the stock trades below the floor of our fair value range.
- Hapvida states there is no decision or signed contract, and the controlling family reportedly resists selling to Bain.
- With the cash loss ratio (sinistralidade) exceeding 77%, every additional percentage point erodes the margins that price adjustments aim to recover.
- The stock still accumulates heavy losses over the past 12 months, pays no dividends, and moves up to 10% in a single day without new fundamental catalysts.
Three indicators will determine whether the rally was substantiated. First is a material fact disclosing a specific transaction value and buyer, transforming a possibility into reality. Second is the 4Q26 loss ratio returning below 75%. Third is leverage halting its upward trajectory. Lacking at least one of these developments, Tuesday's surge was driven by speculation rather than a structural shift in the investment thesis.